BackPhio Pharmaceuticals - Warrants (21/12/2021) Overview

Phio Pharmaceuticals - Warrants (21/12/2021) Total Revenue

Phio Pharmaceuticals - Warrants (21/12/2021)'s total revenue is $0, below the Healthcare sector average of $110B.

Get informed when a big investor buys or sells

+ Follow

Quarterly Revenue

N/A

As of Jun 2026

Annual Revenue (TTM)

N/A

Trailing 12 months ending Jun 2026

Average Revenue (Comparison Companies)

Loading

Total Revenue History

Loading

Total Revenue Comparison

Loading

Annual Revenue Growth Rate (%)

Loading

Annual Revenue Growth (Absolute)

Loading

Phio Pharmaceuticals - Warrants (21/12/2021) (PHIOW) FAQ

The latest total revenue for PHIOW is $0 as of June 2026. In the prior-year period, the figure was $0. That is below the Healthcare sector average of $110B. Investors often review this figure alongside Phio Pharmaceuticals - Warrants (21/12/2021)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, PHIOW's total revenue moved from $0 to $0. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Phio Pharmaceuticals - Warrants (21/12/2021)'s operating scale or balance-sheet position.

Against Healthcare companies, PHIOW currently prints $0 for total revenue, while the sector average sits near $110B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Phio Pharmaceuticals - Warrants (21/12/2021)'s growth, margins, and balance sheet.

A total revenue figure of $0 for PHIOW is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting PHIOW's total revenue ($0), review year-over-year change from $0, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.